Following the results of the UK’s referendum on 23 June, the life sciences industry needs to prepare for the impact of a change in the relationship between the UK and EU. The impact will differ from company to company, but it is possible to shed light on the extent, the timing and who in the industry will be affected, by considering the different activities in the industry value chain and the role of European rules and regulation. To read more, click the link below.
Upper Payment Limits (UPLs) explained
Regulatory shifts create new challenges for pharmaceutical stakeholders. Four states now have PDABs empowered to set UPLs for public payers, and three states...